Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
01 2019
Historique:
received: 13 07 2018
revised: 22 08 2018
accepted: 24 08 2018
pubmed: 30 8 2018
medline: 9 1 2020
entrez: 30 8 2018
Statut: ppublish

Résumé

The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of 39%, representing an estimated 6.1 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts to discuss remaining challenges and future priorities for action from a health systems perspective. The WHO health systems framework comprises six core components: service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance. Communication has been proposed as a seventh key element which promotes the central role of affected community engagement. This review paper presents recommended strategies for eliminating hepatitis C as a major public health threat among PWID and outlines future priorities for action within a health systems framework.

Identifiants

pubmed: 30157316
doi: 10.1111/liv.13949
pmc: PMC6868526
mid: NIHMS987044
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-30

Subventions

Organisme : Department of Health
ID : RP-PG-0616-20008
Pays : United Kingdom
Organisme : NIDA NIH HHS
ID : R01 DA034086
Pays : United States
Organisme : Department of Health
ID : RP-DG-0610-10055
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

J Subst Abuse Treat. 2012 Dec;43(4):424-32
pubmed: 23036920
Int J Drug Policy. 2015 Oct;26(10):992-8
pubmed: 25697089
Clin Infect Dis. 2017 Apr 1;64(7):860-869
pubmed: 28362947
J Viral Hepat. 2012 Dec;19(12):836-42
pubmed: 23121361
Int J Drug Policy. 2015 Oct;26(10):999-1006
pubmed: 26275578
N Engl J Med. 2011 Jun 9;364(23):2199-207
pubmed: 21631316
J Clin Virol. 2014 Nov;61(3):359-64
pubmed: 25264306
Lancet Infect Dis. 2016 Dec;16(12):1409-1422
pubmed: 27615026
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
J Viral Hepat. 2014 May;21 Suppl 1:5-33
pubmed: 24713004
J Gen Intern Med. 2015 Jul;30(7):950-7
pubmed: 25680353
Clin Infect Dis. 2013 Aug;57 Suppl 2:S39-45
pubmed: 23884064
Drug Alcohol Depend. 2016 Dec 01;169:101-109
pubmed: 27810652
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411
pubmed: 27553375
Ann Intern Med. 2017 May 2;166(9):637-648
pubmed: 28319996
Addiction. 2008 Sep;103(9):1484-92
pubmed: 18636999
J Clin Virol. 2012 Jul;54(3):213-7
pubmed: 22560051
Int J Drug Policy. 2015 Oct;26(10):922-35
pubmed: 26077144
Clin Infect Dis. 2013 Aug;57 Suppl 2:S32-8
pubmed: 23884063
Int J Drug Policy. 2015 Oct;26(10):984-91
pubmed: 26256938
Addiction. 2019 Jan;114(1):150-166
pubmed: 30035835
Dig Liver Dis. 2012 Jun;44(6):497-503
pubmed: 22342471
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):514-520
pubmed: 28442271
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Int J Drug Policy. 2015 Nov;26(11):1050-5
pubmed: 26118799
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Ann Intern Med. 2016 Nov 1;165(9):625-634
pubmed: 27537841
Int J Drug Policy. 2017 Sep;47:34-46
pubmed: 28797498
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161
pubmed: 29310928
Drug Alcohol Rev. 2002 Mar;21(1):33-7
pubmed: 12189002
J Infect Dis. 2011 Sep 15;204(6):825-31
pubmed: 21849279
Lancet. 2014 Nov 29;384(9958):1953-97
pubmed: 25433429
Clin Infect Dis. 2011 Oct;53(8):780-6
pubmed: 21921221
Clin Infect Dis. 2016 Mar 15;62(6):683-694
pubmed: 26787172
J Gastroenterol Hepatol. 2014 Jan;29(1):116-20
pubmed: 24033786
J Hepatol. 2018 Mar;68(3):402-411
pubmed: 29080808
Clin Infect Dis. 2013 Aug;57 Suppl 2:S56-61
pubmed: 23884067
J Public Health (Oxf). 2016 Mar;38(1):130-7
pubmed: 25736438
Hepatology. 2012 Jan;55(1):49-57
pubmed: 21898506
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481
pubmed: 27553377
Harm Reduct J. 2008 Feb 25;5:8
pubmed: 18298862
J Health Care Poor Underserved. 2014 May;25(2):652-62
pubmed: 24858874
J Hepatol. 2011 Jun;54(6):1137-44
pubmed: 21145810
Croat Med J. 2016 Oct 31;57(5):442-456
pubmed: 27815935
PLoS One. 2014 Jul 28;9(7):e103345
pubmed: 25068274
J Clin Virol. 2017 Mar;88:46-51
pubmed: 28160728
Expert Rev Mol Diagn. 2017 Dec;17(12):1109-1115
pubmed: 29088981
J Hepatol. 2016 Jul;65(1):17-25
pubmed: 26867489
Addiction. 2011 May;106(5):970-6
pubmed: 21182552
J Viral Hepat. 2015 Jan;22 Suppl 1:6-25
pubmed: 25560839
Addiction. 2015 Jun;110(6):975-83
pubmed: 25586171
Int J Drug Policy. 2017 Sep;47:202-208
pubmed: 28619394
Hepatology. 2013 Nov;58(5):1598-609
pubmed: 23553643
J Infect. 2015 Nov;71(5):571-7
pubmed: 26212868
Clin Infect Dis. 2013 Aug;57 Suppl 2:S75-9
pubmed: 23884070
Clin Infect Dis. 2017 May 1;64(9):1154-1162
pubmed: 28199495
Am J Gastroenterol. 2006 Oct;101(10):2254-62
pubmed: 17032190
J Viral Hepat. 2015 Dec;22 Suppl 4:4-20
pubmed: 26513445
Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7
pubmed: 20425880
Addiction. 2012 Nov;107(11):1984-95
pubmed: 22564041
Clin Infect Dis. 2013 Apr;56(8):1078-84
pubmed: 23362288
Gut. 2003 Oct;52(10):1500-4
pubmed: 12970145
Educ Health (Abingdon). 2006 Nov;19(3):385-7
pubmed: 17178522
Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9
pubmed: 23884071
Br J Gen Pract. 2006 Nov;56(532):848-56
pubmed: 17132352
Am J Epidemiol. 2008 Nov 15;168(10):1099-109
pubmed: 18849303
J Viral Hepat. 2015 Apr;22(4):353-61
pubmed: 25367722
Am J Public Health. 2012 Nov;102(11):e115-21
pubmed: 22994166
Int J Drug Policy. 2017 Sep;47:51-60
pubmed: 28683982
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62
pubmed: 23817321
Hepatology. 2014 Dec;60(6):1861-70
pubmed: 25163856
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Int J Drug Policy. 2015 Oct;26(10):1028-38
pubmed: 26282715
Am J Gastroenterol. 2016 Jun;111(6):903-5
pubmed: 27249993
Drug Alcohol Depend. 2016 Aug 01;165:53-60
pubmed: 27268294
Am J Gastroenterol. 2011 Oct;106(10):1777-86
pubmed: 21769136
J Clin Microbiol. 2017 May;55(5):1550-1556
pubmed: 28275079
Ann Intern Med. 2012 Oct 16;157(8):558-66
pubmed: 23070489
Euro Surveill. 2009 Apr 09;14(14):5-9
pubmed: 19371508
J Viral Hepat. 2017 Oct;24(10):850-857
pubmed: 28345206
J Community Health. 2014 Oct;39(5):922-34
pubmed: 25135842
J Viral Hepat. 2016 May;23(5):399-401
pubmed: 26833561
Drug Alcohol Depend. 2009 Jun 1;102(1-3):158-61
pubmed: 19251382
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):218-30
pubmed: 25782091
Clin Gastroenterol Hepatol. 2015 Nov;13(11):2005-14.e1-3
pubmed: 25724704
Clin Infect Dis. 2013 Aug;57 Suppl 2:S62-9
pubmed: 23884068
Open Forum Infect Dis. 2015 Oct 26;2(4):ofv162
pubmed: 26668814
Int J Drug Policy. 2014 Jan;25(1):34-52
pubmed: 23973009
Int J Drug Policy. 2015 Feb;26 Suppl 1:S5-11
pubmed: 25727260
Int J Drug Policy. 2007 Oct;18(5):406-10
pubmed: 17854729
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Telemed Telecare. 2017 Jan;23(1):83-87
pubmed: 26748393
World J Hepatol. 2016 Apr 18;8(11):509-12
pubmed: 27099651
Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004145
pubmed: 21833948
J Viral Hepat. 2009 Feb;16(2):121-31
pubmed: 19175876
Health Policy Plan. 2014 Sep;29 Suppl 2:ii98-106
pubmed: 25274645
Am J Public Health. 2013 Oct;103(10):e81-8
pubmed: 23947319
J Infect Dis. 2016 Apr 1;213(7):1087-95
pubmed: 26333945
J Hepatol. 2016 May;64(5):1020-1026
pubmed: 26780289
Am J Public Health. 2011 Nov;101(11):2151-5
pubmed: 21940910
Clin Microbiol Infect. 2016 May;22(5):459.e1-6
pubmed: 26806260
Int J Drug Policy. 2017 Sep;47:209-215
pubmed: 28587943
J Viral Hepat. 2016 May;23(5):366-74
pubmed: 26840570
Addiction. 2018 Jan;113(1):173-182
pubmed: 28734093
Int J Drug Policy. 2017 Sep;47:216-220
pubmed: 28666635

Auteurs

Emma Day (E)

Australasian Society for HIV, Viral Hepatitis, and Sexual Health Medicine, Sydney, New South Wales, Australia.

Margaret Hellard (M)

Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.

Carla Treloar (C)

Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.

Julie Bruneau (J)

CHUM Research Centre (CRCHUM), Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.

Natasha K Martin (NK)

Division of Global Public Health, University of California, San Diego, California.

Anne Øvrehus (A)

Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.

Olav Dalgard (O)

Department of Infectious Diseases, Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway.

Andrew Lloyd (A)

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

John Dillon (J)

Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, UK.

Matt Hickman (M)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Jude Byrne (J)

Australian Injecting & Illicit Drug Users League, Canberra, Australian Capital Territory, Australia.

Alain Litwin (A)

University of South Carolina School of Medicine Greenville, Greenville, South Carolina.

Mojca Maticic (M)

Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Philip Bruggmann (P)

Arud Centres for Addiction Medicine, Zürich, Switzerland.

Havard Midgard (H)

Department of Gastroenterology, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.

Brianna Norton (B)

University of South Carolina School of Medicine Greenville, Greenville, South Carolina.

Stacey Trooskin (S)

Philadelphia FIGHT, Philadelphia, Pennsylvania.

Jeffrey V Lazarus (JV)

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

Jason Grebely (J)

The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH